|
|
|
| Therapeutic Effect of Interferon combined with Montelukast and Vitamin D on Asthmatic Bronchitis |
| SUN Meng, GU Mingxiao |
| Qingdao Women’s and Children’s Hospital, Shandong Qingdao 266000, China |
|
|
|
|
Abstract Objective: To observe the efficacy of interferon combined with montelukast and vitamin D in the treatment of asthmatic bronchitis. Methods: A total of 96 children patients with asthmatic bronchitis admitted to pediatric department of our hospital from March 2016 to September 2018 were selected and divided into observation group and control group according to the random number table method, with 48 cases in each group. Control group was given montelukast combined with vitamin D, and observation group was given interferon on this basis, and 7d was taken as one course of treatment. The efficacy and immune function were analyzed in the two groups after the end of one course of treatment, and the adverse drug reactions and recurrence rate within 6 months were observed. Results: The remission times of symptoms of wheezing, cough and lung wheezing rale and hospital stay in observation group were significantly lower than those in control group (P<0.05). There was a statistically significant difference in the clinical efficacy between the two groups (P<0.05), and the total effective rate in observation group was significantly higher than that in control group (92.00% & 76.00%) (P<0.05). After treatment, the levels of IgA, CD4+ and CD4+/CD8+ in the two groups were significantly higher than those before treatment (P<0.05) while the levels of IgE and CD8+ were significantly lower than those before treatment (P<0.05), and the increases of IgA, CD4+ and CD4+/CD8+ and decreases of IgE and CD8+ in observation group were greater than those in control group (P<0.05). There was no significant difference in the incidence rate of adverse reactions between the two groups (8.33% & 6.25%) (P>0.05). Within 6 months, the recurrence rate in observation group was significantly lower than that in control group (4.17% & 18.72%) (P<0.05). Conclusion: Interferon combined with montelukast and vitamin D in the treatment of asthmatic bronchitis can effectively alleviate symptoms, improve clinical efficacy, improve immune function and reduce the recurrence rate of children with asthmatic bronchitis. It is safe and has clinical application value.
|
|
|
|
|
|
[1] 袁艺,曹玲,于雪梅,等.儿科门诊儿童毛细支气管炎及喘息性支气管炎治疗现状[J].中华实用儿科临床杂志,2015,30(4):267~270.
[2] 刘秋云,李黎辉,张和成.干扰素、布地奈德和特布他林联合治疗小儿喘息性支气管炎疗效观察[J].河北医药,2017,39(3):431~433.
[3] 王晶,刘充德,彭梅芳,等.孟鲁司特钠联合匹多莫德治疗对急性支气管炎患儿急性时相蛋白、免疫功能的影响[J].海南医学院学报,2017,23(16):2236~2239.
[4] 徐兰飞,杨耀锋.喘息型支气管炎患儿外周血中25-(OH)D3与IgE浓度水平变化及其发病机制分析[J].中国妇幼保健,2018,33(6):1300~1302.
[5] 胡亚美,江载芳.诸福棠实用儿科学[M].第7版.北京:人民卫生出版社,2002.1203~1204.
[6] 陈世坤,潘军,甘玉荣,等.玉屏风颗粒联合多索茶碱治疗儿童喘息性支气管炎的临床研究[J].现代药物与临床,2018,33(3):546~549.
[7] 张海邻,吕芳芳.病毒性细支气管炎与哮喘相关性研究进展[J].中国实用儿科杂志,2017,32(12):895~900.
[8] 曾义菊,曾令涛,肖洋.小青龙汤治疗小儿喘息样支气管炎的优势及机制探究[J].中华中医药学刊,2017,35(11):2973~2976.
[9] 金瑄,王丽.干扰素α1b联合孟鲁司特钠治疗小儿喘息性支气管炎疗效观察[J].海南医学,2017,28(4):654~655.
[10] 雷玉琳.氨溴特罗口服溶液联合孟鲁司特钠咀嚼片治疗儿童急性支气管炎的临床效果[J].中国医药导报,2017,14(6):124~127.
[11] Tenero L,Boner A L.Vitamin D supplementation in children with asthma[J].Pediatric Allergy and Immunology,2016,27(4):338~339.
[12] 薛秀丽,池红井,冀楠,等.维生素D在喘息性支气管炎发病中的作用[J].河北医学,2016,22(12):2068~2070. |
|
|
|
2019, Vol. 25 
